Skip to main content Accessibility help
×
Hostname: page-component-84b7d79bbc-l82ql Total loading time: 0 Render date: 2024-07-28T07:30:20.473Z Has data issue: false hasContentIssue false

5 - Amantadine

Published online by Cambridge University Press:  06 October 2020

Stephen D. Silberstein
Affiliation:
Thomas Jefferson University, Philadelphia
Michael J. Marmura
Affiliation:
Thomas Jefferson University, Philadelphia
Hsiangkuo Yuan
Affiliation:
Thomas Jefferson University, Philadelphia
Stephen M. Stahl
Affiliation:
University of California, San Diego
Get access

Summary

THERAPEUTICS

Brands

• Symmetrel, Symadine

Generic?

• Yes

Class

• Antiparkinson agent

Commonly Prescribed for

(FDA approved in bold)

Parkinson's disease (PD)

Drug-induced extrapyramidal reactions

Influenza-A prophylaxis/treatment

• Post-encephalitic parkinsonism

• Vascular parkinsonism

• Fatigue in multiple sclerosis (MS)

• Accelerate recovery after traumatic brain injury

• Attention deficit hyperactivity disorder

• SSRI-related sexual dysfunction

• Tardive dyskinesia

How the Drug Works

• The mechanism of action in PD is poorly understood but animal studies suggest either that it induces release or decreases reuptake of dopamine. Also is a weak NMDA receptor antagonist that in animals decreases release of acetylcholine from the striatum. Treats and prevents influenza-A by preventing the release of viral nucleic acid into the host cell by interfering with the function of a viral M2 protein. It may also prevent virus assembly during replication

How Long Until It Works

• PD: 48 hours or less

If It Works

• PD: most patients require dose adjustment over time and will need to take other agents, such as levodopa

If It Doesn't Work

• PD: motor symptoms, such as bradykinesia, gait, and tremor should improve. Reduces extrapyramidal reactions, such as dyskinesias, and can allow reduction of carbidopa-levodopa doses. Non-motor symptoms, including autonomic symptoms such as postural hypotension, depression, and bladder dysfunction, do not improve. If the patient has significantly impaired functioning, add levodopa or a dopamine agonist

• Fatigue: MS-related fatigue may respond to stimulants or modafinil

Best Augmenting Combos for Partial Response or Treatment-Resistance

• For suboptimal effectiveness add carbidopalevodopa with or without a catechol-Omethyltransferase (COMT) inhibitor or dopamine agonist depending on disease severity. Monoamine oxidase (MAO)-B inhibitors may also be beneficial

• For younger patients with bothersome tremor anticholinergics may help

• For severe motor fluctuations and/or dyskinesias with good “on” time, functional neurosurgery is an option

Type
Chapter
Information
Essential Neuropharmacology
The Prescriber's Guide
, pp. 17 - 20
Publisher: Cambridge University Press
Print publication year: 2015

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

Save book to Kindle

To save this book to your Kindle, first ensure coreplatform@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about saving to your Kindle.

Note you can select to save to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

  • Amantadine
  • Stephen D. Silberstein, Thomas Jefferson University, Philadelphia, Michael J. Marmura, Thomas Jefferson University, Philadelphia, Hsiangkuo Yuan, Thomas Jefferson University, Philadelphia
  • Edited in consultation with Stephen M. Stahl, University of California, San Diego
  • Book: Essential Neuropharmacology
  • Online publication: 06 October 2020
  • Chapter DOI: https://doi.org/10.1017/9781316161753.006
Available formats
×

Save book to Dropbox

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Dropbox.

  • Amantadine
  • Stephen D. Silberstein, Thomas Jefferson University, Philadelphia, Michael J. Marmura, Thomas Jefferson University, Philadelphia, Hsiangkuo Yuan, Thomas Jefferson University, Philadelphia
  • Edited in consultation with Stephen M. Stahl, University of California, San Diego
  • Book: Essential Neuropharmacology
  • Online publication: 06 October 2020
  • Chapter DOI: https://doi.org/10.1017/9781316161753.006
Available formats
×

Save book to Google Drive

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Google Drive.

  • Amantadine
  • Stephen D. Silberstein, Thomas Jefferson University, Philadelphia, Michael J. Marmura, Thomas Jefferson University, Philadelphia, Hsiangkuo Yuan, Thomas Jefferson University, Philadelphia
  • Edited in consultation with Stephen M. Stahl, University of California, San Diego
  • Book: Essential Neuropharmacology
  • Online publication: 06 October 2020
  • Chapter DOI: https://doi.org/10.1017/9781316161753.006
Available formats
×